A 32-year-old woman with anovulatory infertility secondary to PCOS is being counseled on ovulation induction options. All of the following are recognized advantages or appropriate indications for the listed agents EXCEPT:

Explanation

## Ovulation Induction in PCOS — Evidence-Based Approach ### The Incorrect Statement (Answer: C) **High-Yield:** Option C is the EXCEPT answer because it contains a factually incorrect claim. According to the **ESHRE/ASRM 2023 International Evidence-based Guideline for PCOS**: - **Metformin is NOT recommended as first-line therapy in ALL PCOS phenotypes** for ovulation induction. - **Letrozole** is the recommended first-line agent for ovulation induction in PCOS (ESHRE 2023), not metformin. - In **lean PCOS patients**, metformin's benefit for ovulation induction is modest and inconsistent; letrozole or clomiphene are preferred for ovulation induction. - Metformin is primarily indicated for **metabolic benefits** (insulin resistance, hyperandrogenism) and as an **adjunct** to ovulation induction agents, particularly in obese/insulin-resistant PCOS. - The claim that metformin "is recommended as first-line therapy in all PCOS phenotypes" is an overstatement of its evidence base and is factually incorrect. ### Why the Other Options Are Correct Statements **Key Point — Option A:** GnRH **agonist** co-treatment with gonadotropins carries a **higher** risk of OHSS compared to GnRH **antagonist** protocols in PCOS. This is because agonists cause an initial "flare" of endogenous gonadotropins, increasing stimulation of already hypersensitive PCOS ovaries. GnRH antagonist protocols are therefore **preferred** in PCOS undergoing IVF/gonadotropin stimulation. Option A correctly identifies this distinction — agonist protocols increase OHSS risk, making it a true (non-exception) statement. | Protocol | GnRH Agent | OHSS Risk in PCOS | Preferred in PCOS? | | --- | --- | --- | --- | | Long protocol | Agonist | Higher | No | | Short/flexible protocol | Antagonist | Lower | **Yes** | **Clinical Pearl — Option B:** Inositol supplementation (myo-inositol and D-chiro-inositol) improves insulin signaling, reduces androgen levels, and enhances ovulation rates in PCOS. The combination of inositol with metformin is synergistic and is increasingly recognized in guidelines for PCOS management *(Unfer et al., 2017)*. Option B is a correct statement. **Key Point — Option D:** Letrozole is preferred over clomiphene in PCOS because: - It does not deplete estrogen receptors (unlike clomiphene's anti-estrogenic mechanism). - It has a shorter half-life, reducing cumulative anti-estrogenic endometrial effects. - It reduces the risk of multiple follicle recruitment and OHSS. - The landmark **Legro et al. (NEJM 2014)** trial demonstrated higher live birth rates and lower miscarriage rates with letrozole compared to clomiphene in PCOS. - Option D is a correct statement. **Mnemonic:** **LETROZOLE = LEADING CHOICE** for ovulation induction in PCOS; metformin = metabolic adjunct, not universal first-line for all phenotypes. *References: ESHRE/ASRM International Evidence-based Guideline for PCOS 2023; Legro RS et al., NEJM 2014; KD Tripathi Essentials of Medical Pharmacology, 8th ed.*